Jay Khambhati, MD, is an interventional cardiologist who specializes in catheter-based management and treatments for patients with structural heart disease and complex coronary artery disease.
With a passion for advancing heart care, Dr. Khambhati is committed to delivering an approach to care that combines the latest medical innovations with a deep understanding of each patient’s unique needs. Dr. Khambhati’s expertise and experience allow him to develop personalized and effective treatment plans for his patients, which includes performing:
Transcatheter aortic valve replacement
Transcatheter mitral valve replacement and edge to edge repair
Transcatheter tricuspid valve replacement and edge to edge repair
Patent foramen ovale and atrial septal defect closure
Paravalvular leak closure
Left atrial appendage closure
Balloon valvuloplasty
Percutaneous coronary intervention
Alcohol Septal Ablation
In addition to his clinical practice, Dr. Khambhati is actively researching new methods and techniques designed to improve care for his patients. Through his research, Dr. Khambhati investigates the durability of transcatheter aortic valves, the rate of progression of aortic valve stenosis, hypoattenuating leaflet thickening (HALT) after TAVR, and the use of intravascular imaging and calcium modification in acute coronary syndromes. Dr. Khambhati has also worked on machine learning models to detect the presence and severity of regurgitant valve lesions in echocardiography. He has served as a co-investigator on large multicenter clinical trials investigating novel therapies in interventional cardiology.
Long-term risk of adverse limb outcomes in older patients after endovascular femoral artery revascularization: The Boston femoral artery endovascular revascularization outcomes (Boston FAROUT) study.
Long-term risk of adverse limb outcomes in older patients after endovascular femoral artery revascularization: The Boston femoral artery endovascular revascularization outcomes (Boston FAROUT) study. Cardiovasc Revasc Med. 2025 Nov; 80:108-112.
PMID: 39779402
Extracorporeal Femoro-Carotid Shunt for Transcarotid Transcatheter Aortic Valve Replacement.
Extracorporeal Femoro-Carotid Shunt for Transcarotid Transcatheter Aortic Valve Replacement. JACC Case Rep. 2024 Jun 19; 29(12):102371.
PMID: 38779554
Assessment of valve regurgitation severity via contrastive learning and multi-view video integration.
Assessment of valve regurgitation severity via contrastive learning and multi-view video integration. Phys Med Biol. 2024 Feb 12; 69(4).
PMID: 38271727
Shielding for Radiation Safety in the Cardiac Catheterization Laboratory.
Shielding for Radiation Safety in the Cardiac Catheterization Laboratory. Circ Cardiovasc Interv. 2023 12; 16(12):e013647.
PMID: 37955162
Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system.
Early clinical and sociodemographic experience with patients hospitalized with COVID-19 at a large American healthcare system. EClinicalMedicine. 2020 Sep; 26:100504.
PMID: 32838244
Marital status and outcomes in patients with cardiovascular disease.
Marital status and outcomes in patients with cardiovascular disease. Trends Cardiovasc Med. 2020 05; 30(4):215-220.
PMID: 31204239
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk.
HDL: Fact, fiction, or function? HDL cholesterol and cardiovascular risk. Eur J Prev Cardiol. 2021 04 10; 28(2):166–173.
PMID: 33838035
Re: The art of cardiovascular risk assessment. Clinical Cardiology 2018;41(5):677-684.
Re: The art of cardiovascular risk assessment. Clinical Cardiology 2018;41(5):677-684. Clin Cardiol. 2018 08; 41(8):1111.
PMID: 29920711
Reconfiguring Cardiac Rehabilitation to Achieve Panvascular Prevention: New Care Models for a New World.
Reconfiguring Cardiac Rehabilitation to Achieve Panvascular Prevention: New Care Models for a New World. Can J Cardiol. 2018 10; 34(10 Suppl 2):S231-S239.
PMID: 30274634
Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities.
Immunotherapy for the prevention of atherosclerotic cardiovascular disease: Promise and possibilities. Atherosclerosis. 2018 09; 276:1-9.
PMID: 30006321